Curida and PCI Biotech have entered into a manufacturing agreement

Published: 01 Jul 2016

The pharmaceutical Contract Development and Manufacturing Organization Curida has entered into a manufacturing agreement with the Norwegian biotech company PCI Biotech. Curida will manufacture Amphinex, the lead product candidate from PCI Biotech. Amphinex is currently undergoing international clinical trials for bile duct cancer, a rare cancer disease with a high need of better treatment options.

– The Curida organisation has long experience in manufacturing of sterile pharmaceuticals and a proven track record for manufacturing according to the highest quality standards. Curida also operates at a competitive price level. We are therefore very happy to enter into this agreement for our lead product candidate, says Per Walday, CEO of PCI Biotech.

– Entering into partnerships with biotech companies at an early stage is part of our long-term growth strategy. PCI Biotech is one of the companies that we hope to see succeed with their innovations, and with this partnership we will be in position to provide the services they need when entering large markets, says Leif Rune Skymoen, CEO of Curida.